252 related articles for article (PubMed ID: 26254911)
1. A Physiologically Based Pharmacokinetic Model of Amiodarone and its Metabolite Desethylamiodarone in Rats: Pooled Analysis of Published Data.
Lu JT; Cai Y; Chen F; Jia WW; Hu ZY; Zhao YS
Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):689-703. PubMed ID: 26254911
[TBL] [Abstract][Full Text] [Related]
2. Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone.
Chen Y; Mao J; Hop CE
Drug Metab Dispos; 2015 Feb; 43(2):182-9. PubMed ID: 25324279
[TBL] [Abstract][Full Text] [Related]
3. The effect of CYP1A induction on amiodarone disposition in the rat.
Elsherbiny ME; Brocks DR
J Pharm Sci; 2010 Jan; 99(1):539-48. PubMed ID: 19718765
[TBL] [Abstract][Full Text] [Related]
4. Determination of the enzyme(s) involved in the metabolism of amiodarone in liver and intestine of rat: the contribution of cytochrome P450 3A isoforms.
Shayeganpour A; El-Kadi AO; Brocks DR
Drug Metab Dispos; 2006 Jan; 34(1):43-50. PubMed ID: 16204463
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of desethylamiodarone in the rat after its administration as the preformed metabolite, and after administration of amiodarone.
Shayeganpour A; Hamdy DA; Brocks DR
Biopharm Drug Dispos; 2008 Apr; 29(3):159-66. PubMed ID: 18161885
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetic investigation for optimization of amiodarone therapy in Japanese patients.
Araki R; Yukawa E; Nakashima MN; Fukuchi H; Sasaki H; Yano K; Nakashima M
Ther Drug Monit; 2011 Dec; 33(6):750-6. PubMed ID: 22105593
[TBL] [Abstract][Full Text] [Related]
7. Serum amiodarone and desethylamiodarone concentrations following nasogastric versus oral administration.
Kotake T; Takada M; Goto T; Komamura K; Kamakura S; Morishita H
J Clin Pharm Ther; 2006 Jun; 31(3):237-43. PubMed ID: 16789989
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and body distribution of amiodarone and desethylamiodarone in rats after oral administration.
Plomp TA; Wiersinga WM; Van Rossum JM; Maes RA
In Vivo; 1987; 1(5):265-79. PubMed ID: 2979794
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and body distribution of amiodarone and desethylamiodarone in rats after intravenous administration.
Plomp TA; Wiersinga WM; van Rossum JM; Maes RA
In Vivo; 1989; 3(1):33-47. PubMed ID: 2519831
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of intravenous amiodarone and its electrocardiographic effects on healthy Japanese subjects.
Shiga T; Tanaka T; Irie S; Hagiwara N; Kasanuki H
Heart Vessels; 2011 May; 26(3):274-81. PubMed ID: 21052689
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of amiodarone (part I): identification of a new hydroxylated metabolite of amiodarone.
Ha HR; Bigler L; Binder M; Kozlik P; Stieger B; Hesse M; Altorfer HR; Follath F
Drug Metab Dispos; 2001 Feb; 29(2):152-8. PubMed ID: 11159805
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of long-term oral amiodarone therapy.
Pollak PT; Bouillon T; Shafer SL
Clin Pharmacol Ther; 2000 Jun; 67(6):642-52. PubMed ID: 10872646
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the pharmacokinetics and bioavailability of intravenously and orally administered amiodarone in horses.
De Clercq D; Baert K; Croubels S; van Loon G; Maes A; Tavernier R; Deprez P; De Backer P
Am J Vet Res; 2006 Mar; 67(3):448-54. PubMed ID: 16506906
[TBL] [Abstract][Full Text] [Related]
14. Prediction of the dose range for adverse neurological effects of amiodarone in patients from an in vitro toxicity test by in vitro-in vivo extrapolation.
Algharably EAE; Di Consiglio E; Testai E; Kreutz R; Gundert-Remy U
Arch Toxicol; 2021 Apr; 95(4):1433-1442. PubMed ID: 33606068
[TBL] [Abstract][Full Text] [Related]
15. Single-dose kinetics of tissue distribution, excretion and metabolism of amiodarone in rats.
Wyss PA; Moor MJ; Bickel MH
J Pharmacol Exp Ther; 1990 Aug; 254(2):502-7. PubMed ID: 2384884
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamic effects of amiodarone in plasma of ponies after single intravenous administration.
Trachsel D; Tschudi P; Portier CJ; Kuhn M; Thormann W; Scholtysik G; Mevissen M
Toxicol Appl Pharmacol; 2004 Feb; 195(1):113-25. PubMed ID: 14962511
[TBL] [Abstract][Full Text] [Related]
17. Long-term pretreatment with desethylamiodarone (DEA) or amiodarone (AMIO) protects against coronary artery occlusion induced ventricular arrhythmias in conscious rats.
Morvay N; Baczkó I; Sztojkov-Ivanov A; Falkay G; Papp JG; Varró A; Leprán I
Can J Physiol Pharmacol; 2015 Sep; 93(9):773-7. PubMed ID: 26176275
[TBL] [Abstract][Full Text] [Related]
18. The impact of experimental hyperlipidemia on the distribution and metabolism of amiodarone in rat.
Shayeganpour A; Korashy H; Patel JP; El-Kadi AO; Brocks DR
Int J Pharm; 2008 Sep; 361(1-2):78-86. PubMed ID: 18599227
[TBL] [Abstract][Full Text] [Related]
19. Effect of obesity on serum amiodarone concentration in Japanese patients: population pharmacokinetic investigation by multiple trough screen analysis.
Fukuchi H; Nakashima M; Araki R; Komiya N; Hayano M; Yano K; Sasaki H; Yukawa E
J Clin Pharm Ther; 2009 Jun; 34(3):329-36. PubMed ID: 19646079
[TBL] [Abstract][Full Text] [Related]
20. Disposition of intravenous amiodarone in subjects with normal and impaired renal function.
Ujhelyi MR; Klamerus KJ; Vadiei K; O'Rangers E; Izard M; Neefe DL; Zimmerman JJ; Chow MS
J Clin Pharmacol; 1996 Feb; 36(2):122-30. PubMed ID: 8852388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
